Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung CancerTony Mok, Vassiliki A. Papadimitrakopoulou, Yi‐Long Wu et al.|New England Journal of Medicine|2016Cited by 3.3k
Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancerJae-Won Cho, Hye Ryun Kim|Experimental & Molecular Medicine|2020Cited by 282
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinomaHye Ryun Kim, Byoung Chul Cho, Seungtaek Lim et al.|Annals of Oncology|2013Cited by 125
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung CancerMi Ran Yun, Byoung Chul Cho, Sung Sook Lee et al.|Clinical Cancer Research|2020Cited by 116